You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Product menu

Havrix Junior Long-term protection

Havrix Junior: up to 50 years of predicted long-term immunity*1,2

Two doses of Havrix Junior are predicted to provide long-term protection of at least up to 50 years following childhood administration1,2

Hepatitis A and its shifting endemicity

Globe Icon

Over 100 million hepatitis A infections are estimated to occur annually worldwide3

Hepatitis A infection is more severe with increasing age3,4

UNDERSTAND THE BURDEN OF HEPATITIS A

Paradox of shifting endemicity icon

The paradox of shifting endemicity

As low-income regions (in sub-Saharan Africa and parts of South Asia) and middle-income regions (in Asia, Latin America, Eastern Europe and the Middle East) transition from high to intermediate endemicity, their incidence of clinically significant hepatitis A increases5

DISCOVER THE PARADOX

The importance of prevention and vaccination

Vaccination is one of the best ways to help prevent hepatitis A infection5,6

Hepatitis A vaccines

Photo of laboratory staff holding blood tests

Rapid and long-term protection with Havrix Junior1,2,7

Havrix Junior is expected to help provide long-term protection1

FIND OUT MORE ABOUT HAVRIX JUNIOR

Photo of vaccine administration in the arm

A summary of hepatitis A vaccines

A quick reference guide to hepatitis A vaccines

REVIEW THE EVIDENCE

The impact of universal Vaccination

The impact of universal vaccination against hepatitis A

Universal vaccination programmes in countries with intermediate endemicity can help protect individuals from hepatitis A infection and disease and reduce virus circulation8

See the impact

*A descriptive analysis was used to predict long-term seropositivity results for children based on studies of vaccines containing inactivated hepatitis A antigen either as standalone hepatitis A vaccine or combination hepatitis A and B vaccine. In order to extrapolate outcomes in children using data in adults, studies with data on adult vaccine doses of hepatitis A and B vaccine 720 EU or hepatitis A vaccine 1,440 EU were selected2

References

  1. Havrix Junior SmPC, January 2022.
  2. Agrawal A et al. Infect Dis Ther 2020; 9:785–796.
  3. World Health Organization (WHO). WHO immunological basis for immunization series. Module 18: Hepatitis A. Available at: https://apps.who.int/iris/bitstream/handle/10665/326501/97892516327-eng.pdf (Accessed April 2023). 
  4. World Health Organization (WHO). Hepatitis A key facts. Available at: https://www.who.int/news-room/fact-sheets/detail/hepatitis-a (Accessed April 2023).
  5. World Health Organization. Wkly Epidemiol Rec 2022; 97:493–512.
  6. Centers for Disease Control and Prevention (CDC). Hepatitis A questions and answers for the public. Available at: https://www.cdc.gov/hepatitis/hav/afaq.htm#prevent (Accessed April 2023).
  7. Van Der Meeren O et al. Hum Vaccin Immunother 2015; 11:1729–1734.
  8. Stuurman AL et al. Hum Vaccin Immunother 2017; 13:724–736.

For more information, please refer to the prescribing information or contact GlaxoSmithKline
via gcc.medinfo@gsk.com
To report Adverse Event/s associated with the use of GSK product/s, please contact us via
gulf.safety@gsk.com
To report quality complaint/s associated with the use of GSK product/s, please contact us via
 Gulf.ProductQualityComplaints@gsk.com

GlaxoSmithKline Biologicals SA. Rixensart, Belgium
© 2023 GSK group of companies or its licensor
Trademark is owned by or licensed to the GSK group of companies

PM-RCH-HAV-WCNT-230002 | Date of preparation: Noember 2023